Eli Lilly and Company (LLY) is set to acquire Verve Therapeutics, Inc. in a definitive agreement.
Lilly will launch a tender offer to buy all outstanding Verve shares at $10.50 each in cash, valuing the deal at approximately $1.0 billion.
This purchase price includes a premium of about 113%.
Ruth Gimeno, Lilly’s group vice president, highlighted that VERVE-102 has the potential to become the first in vivo gene editing therapy for a broad patient population.
She noted that this breakthrough could revolutionize cardiovascular disease treatment by shifting from ongoing chronic care to a single, definitive therapy.
The transaction is expected to close in the third quarter of 2025.
